Gsk (GLAXF) Net Margin (2009 - 2026)
Gsk (GLAXF) recorded quarterly Net Margin of 22.77% in Q1 2026, up 208.52% quarter-over-quarter from 7.38% in Q4 2025, and up 116.0% on a YoY basis from 10.54% in Q1 2025.
Gsk (GLAXF) Net Margin (2009 - 2026) Analysis & Trends
Gsk's Net Margin history runs 18 years deep, the most recent figure standing at 22.77% for Q1 2026.
- In Q1 2026, Net Margin rose 116.0% year-over-year to 22.77%; the TTM figure through Mar 2026 stood at 17.82% (up 507.0% YoY), while the FY2025 annual figure was 17.5%, up 929.0% from the prior year.
- Net Margin was 22.77% for Q1 2026 at Gsk, up from 7.38% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 138.22% in Q3 2022 to a low of 0.72% in Q3 2024.
- Historically, Net Margin has averaged 29.51% across 5 years, with a median of 21.44% in 2023.
- The sharpest annual moves came in 2022 and 2023: Net Margin jumped 12059 bps in 2022, then plunged 12025 bps in 2023.
- A 5-year view of Net Margin shows it stood at 105.93% in 2022, then plunged by 79 bps to 22.04% in 2023, then plunged by 34 bps to 14.55% in 2024, then slumped by 49 bps to 7.38% in 2025, then surged by 209 bps to 22.77% in 2026.
- The last three Net Margin figures came in at 22.77% (Q1 2026), 7.38% (Q4 2025), and 23.55% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 22.77% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 37.36% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 21.76% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 4.65% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -25.84% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 21.11% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 29.04% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -0.56% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 23.32% |
| 10 | Gsk | - | - | 7.76 Bn | 22.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22.77% |
| Dec 31, 2025 | 7.38% |
| Sep 30, 2025 | 23.55% |
| Jun 30, 2025 | 18.07% |
| Mar 31, 2025 | 21.61% |
| Dec 31, 2024 | 14.55% |
| Sep 30, 2024 | -0.72% |
| Jun 30, 2024 | 14.88% |
| Mar 31, 2024 | 14.21% |
| Dec 31, 2023 | 22.04% |
| Sep 30, 2023 | 17.97% |
| Jun 30, 2023 | 22.62% |
| Mar 31, 2023 | 21.44% |
| Dec 31, 2022 | 105.93% |
| Sep 30, 2022 | 138.22% |
| Jun 30, 2022 | 12.09% |
| Mar 31, 2022 | 25.06% |
| Dec 31, 2021 | 10.59% |
| Sep 30, 2021 | 17.62% |
| Jun 30, 2021 | 23.90% |